DKSH and Merdury Biopharmaceutical Corporation have entered into a partnership to supply Merdury’s Metformin to the Vietnamese market. The product will be distributed by local distribution partners after importation.
Ho Chi Minh City, August 9, 2023 – DKSH, a leading Market Expansion Services Provider, has successfully signed a Memorandum of Understanding (MoU) with Merdury Biopharmaceutical Corporation (Merdury) to bring Metformin, a rapid-acting treatment for type 2 diabetes, to Vietnam.
With broad industry knowledge, in-depth market insight, and a strong network, DKSH will support Merdury with procedures to access the market. Once imported, the product will then be distributed by local distribution partners.
Founded in July 2019, Merdury focuses on the development of drugs for unmet medical needs. With its proprietary StackDose™ platform, which is developed based on a 3D powder printing technology and process, and a unique drug binding formula, Merdury develops new tablet dosage forms with controlled time dissolution and precise site absorption. Drugs manufactured by Merdury also improve the bioavailability of active pharmaceutical ingredients (APIs) to optimize their effects, thereby reducing the dosage of drugs used and thus reducing side effects.
Edward Lin, Chairman of Merdury Biopharmaceutical shared at the signing ceremony: “Vietnam is one of our key markets as we aim to expand our presence outside Taiwan with our advanced diabetes treatment. We highly value DKSH’s expertise and its capillary network of partners in Vietnam, which we believe, is strategic to our future growth in this exciting market.”
Phillip Wray, General Director, DKSH Pharma Vietnam, stated: “This MoU marks the first important step on our shared journey of bringing rapid-acting treatment for type 2 diabetes to the Vietnamese market. We are excited to be Merdury’s trusted partner, and we are thrilled that diabetes patients in Vietnam will soon have better access to more treatment options.”
About Merdury Biopharmaceutical Corporation
Merdury Biopharmaceutical Corporation is listed on Taipei Exchange (TPEx:6932). In order to provide the unmet medical needs in the market and improve public health, we uphold the core business philosophy of "professionalism, efficiency, and internationalization" and commercialize our self-developed drugs and services through professional partnerships in order to provide patients with a more effective drug treatment experience. The Stackdose™ 3D printing pharmaceutical equipment integrates 3D printing technology into pharmaceutical production. It offers the capability to customize the density, structure, and even the arrangement of excipients and APIs within the drug tablets. This revolutionary technology holds tremendous potential to significantly benefit all mankind. https://www.en.merdury.com/
About DKSH
DKSH’s purpose is to enrich people’s lives. For more than 150 years, we have been delivering growth for companies in Asia and beyond across our Business Units Healthcare, Consumer Goods, Performance Materials, and Technology. As a leading Market Expansion Services provider, we offer sourcing, market insights, marketing and sales, eCommerce, distribution and logistics as well as after-sales services. DKSH is a participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business. Listed on the SIX Swiss Exchange, DKSH operates in 37 markets with 32,600 specialists, generating net sales of CHF 11.3 billion in 2022. The DKSH Business Unit Healthcare is a trusted healthcare solutions partner across Asia and beyond. With around 7,990 specialists, the Business Unit generated net sales of CHF 5.6 billion in 2022. www.dksh.com/hec